Supplementary Table 1. Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort
datasetposted on 20.05.2021, 08:28 by Jean-Philippe Metges, Dominique Genet, David Tougeron, Catherine Ligeza, Michel Ducreux, Christophe Borg, Rosine Guimbaud, Jean-Marc Phelip, Louis-Marie Dourthe, Stefano Kim
Supplementary Table 1. Patient demographics and baseline characteristics in the French cohort of the CORRELATE study, stratified by regorafenib starting dose.